

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tab-Cel®



Pierre Fabre to Commercialize Tab-cel® for EBV+ Cancers in Europe, Middle East, Africa, and Other Select Emerging Markets



- Pierre Fabre brings significant oncology commercialization capabilities in the territory
- Tab-cel® will benefit from Pierre Fabre Oncology Business Unit while leveraging its network in Bone Marrow Transplant and track record of partnerships
- Atara will retain full commercialization rights to Tab-cel® in other major markets, including North America, Asia Pacific and Latin America
- Collaboration maximizes the current opportunity for Tab-cel® outside the U.S., while avoiding commercial infrastructure build and complexity for Atara in Europe
- Atara to receive upfront payment of \$45 million, and up to ~\$320 million in milestones, plus significant double-digit tiered royalties as a percentage of net sales
- Atara will continue to be responsible for the pivotal ALLELE study in PTLD as well as submitting the Europe Marketing Authorization Application (MAA)
- Pierre Fabre will lead all commercialization and distribution activities in its territory, as well as medical and regulatory activities after the anticipated MAA approval in Europe

Tab-cel®, recently granted EMA accelerated assessment, remains on-track for EU MAA filing in Nov 2021

